Radiopharm Theranostics Limited
RADX
$7.03
-$0.42-5.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 630.83% | 617.17% | -- | -- | -- |
| Total Other Revenue | 416.19% | 410.25% | -74.08% | -73.48% | -221.84% |
| Total Revenue | 564.85% | 556.19% | -40.05% | -38.65% | -206.70% |
| Cost of Revenue | 137.54% | 133.10% | 0.70% | 3.06% | -42.04% |
| Gross Profit | 34.25% | 35.48% | -15.72% | -18.42% | 6.89% |
| SG&A Expenses | 20.74% | 18.48% | -12.43% | -10.37% | -10.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.44% | 71.17% | -3.86% | -1.61% | -28.35% |
| Operating Income | 8.39% | 10.10% | -3.86% | -6.29% | 8.55% |
| Income Before Tax | 21.41% | 22.88% | 20.98% | 19.13% | -3.41% |
| Income Tax Expenses | -96.74% | -96.73% | 222.55% | 231.37% | 2,250.00% |
| Earnings from Continuing Operations | 21.62% | 23.08% | 20.67% | 18.82% | -3.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.91% | 19.43% | -15.54% | -13.58% | -- |
| Net Income | 21.45% | 22.92% | 20.90% | 19.06% | -8.57% |
| EBIT | 8.39% | 10.10% | -3.86% | -6.29% | 8.55% |
| EBITDA | 5.82% | 7.58% | -4.51% | -6.95% | 8.71% |
| EPS Basic | 85.00% | 85.56% | 85.96% | 85.59% | 18.18% |
| Normalized Basic EPS | 83.72% | 83.72% | 81.31% | 81.31% | 14.85% |
| EPS Diluted | 85.00% | 85.56% | 85.96% | 85.59% | 18.18% |
| Normalized Diluted EPS | 83.72% | 83.72% | 81.31% | 81.31% | 14.85% |
| Average Basic Shares Outstanding | 423.23% | 423.23% | 459.16% | 459.16% | 32.71% |
| Average Diluted Shares Outstanding | 423.23% | 423.23% | 459.16% | 459.16% | 32.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |